NCT02201303View on ClinicalTrials.gov

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 13, 2014

Primary Completion Date

July 2, 2015

Study Completion Date

July 2, 2015

Conditions
Infections, Respiratory Syncytial Virus
Interventions
DRUG

Danirixin

Powdered form for in-vitro administration to blood sample

OTHER

CXCL1

Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.

Trial Locations (1)

13210

GSK Investigational Site, Syracuse

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02201303 - Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression | Biotech Hunter | Biotech Hunter